论文部分内容阅读
目的:通过对癫痫患者的381例次卡马西平血药浓度监测结果分析,为临床合理用药提供参考。方法:采用荧光偏振免疫法测定卡马西平血药浓度,对347例患者的381例次血药浓度进行分析,并观察其临床疗效和不良反应。结果:卡马西平血药浓度测定值在4～12mg·L-1内的有311例次(82.1%),单用卡马西平与合用其它抗癫痫药物时分别有274、37例次,其中有91.6%的可基本控制癫痫发作或改善,3.9%的出现不良反应;低于4mg·L-1的有51例次(13.4%);高于12mg·L-1的有19例次(5.0%),其中有84.2%的出现严重不良反应。结论:卡马西平有效血药浓度范围设为4～12mg·L-1是比较合理的,临床治疗过程中加强卡马西平的血药浓度监测是保证疗效和安全的重要措施。
OBJECTIVE: To provide a reference for clinical rational drug use by analyzing 381 cases of carbamazepine plasma concentration monitoring results of epilepsy patients. Methods: The plasma concentration of carbamazepine was determined by fluorescence polarization immunoassay. The plasma concentrations of 381 patients in 347 patients were analyzed, and the clinical efficacy and adverse reactions were observed. Results: The plasma concentration of carbamazepine was 311 cases (82.1%) in 4 ~ 12 mg · L -1, 274 and 37 cases in carbamazepine alone and in combination with other antiepileptic drugs There were 91.6% could seizure or improve the basic control, 3.9% of the adverse reactions; 51 cases (13.4%) less than 4mg · L-1; 19 cases more than 12mg · L-1 %), Of which 84.2% had serious adverse reactions. CONCLUSION: It is reasonable to set the effective plasma concentration of carbamazepine in the range of 4 ~ 12 mg · L-1. The monitoring of plasma concentration of carbamazepine during clinical treatment is an important measure to ensure curative effect and safety.